229962-55-4

Basic information

• Product Name: raffionse undecaisobutyrate
• CAS NO: 229962-55-4
• Molecular Weight: 1275.44
• Mol File: 229962-55-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: raffionse undecaisobutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: raffionse undecaisobutyrate(229962-55-4)
• EPA Substance Registry System: raffionse undecaisobutyrate(229962-55-4)

Safety Data

• Hazardous Substances Data: 229962-55-4(Hazardous Substances Data)

Upstream product

• 1468-39-9 Isovaleric anhydride 
• 6227-50-5 α-D-galactopyranosyl-(1->6)-O-α-D-glucopyranosyl-(1->2)-β-D-fructofuranoside pentahydrate 
• 97-72-3 2-Methylpropionic anhydride 
• 512-69-6 D-raffinose 

Relevant articles and documents

PALPABLE MARKER COMPOSITION

The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body. In another embodiment the composition is a liquid before administration and has the ability to transform into a crystalline or amorphous solid after administration.

GEL FORMULATIONS FOR IMPROVING IMMUNOTHERAPY

The present invention relates to a composition for use as controlled release of at least one active pharmaceutical ingredient that modulates an immunogenic response in a human or animal body, said composition comprising non-water soluble carbohydrates and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration.